Xentuzumab - Boehringer Ingelheim
Alternative Names: BI-836845Latest Information Update: 11 Aug 2023
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Eli Lilly and Company
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor I inhibitors; Insulin-like growth factor II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HER2 negative breast cancer
- Phase I/II Prostate cancer
- No development reported Breast cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 14 Jul 2023 Boehringer Ingelheim completes phase I trial in Solid tumours (late-stage disease) in Japan (NCT02145741)
- 14 Jul 2023 Boehringer Ingelheim completes a phase I trial in Solid tumours in Japan (NCT02145741)
- 01 Jun 2023 Boehringer Ingelheim completes a phase I trial in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory) in USA, the UK, Netherlands, Spain, Hong Kong, South Korea, Taiwan and Singapore (NCT02204072) (EudraCT2013-004011-41)